Poster Presenter

Retrospective Analysis of Complex Treatment of Patients with Rectal Cancer
A.V.Borota, A.W.Nowicky, A.A.Borota


We performed a randomized investigation of clinical efficacy of newly produced anticancer drug Ukrain, which is characterized like a potent immunomodulating and cancer-suppressing agent.

In the course of investigation we compared two identical groups of RC-patients, each comprised 24 peoples. Patients of the I group received Ukrain in dose of 60 mg i/v before surgical intervention, then operation was performed, after that another dose of Ukrain (40 mg i/v) was repeatedly injected. Patients of the II group were underwent to alternative (traditional) scheme of treatment: administration of 5-fluoruracyl (5000 mg) in combination with the course of radial therapy (25 Gr) was followed by surgical intervention, then 5-fluoruracyl (5000 mg) was injected again. Patients of the I group was found to be in better clinical state. Course of non-adjuvant chemotherapy led to improving as general state of patients, as parameters of their immunological status (IgA, IgM, IgG; T-B-lymphocytes, phagocytic activity; CIC; AFP; CEA).

Radical surgical interventions-resection of the rectum in different modification were performed to patients of both groups. Course of postoperative period proved to be more favorable in patients of the I group. Occurrence of postoperative complications (purulent-inflammatory in main) constituted 8,3% in I and 16,7% in II group of patients. Postponed results of complex treatment of RC-patients were more favorable on background of Ukrain chemotherapy as well. 12-years survival in patients of the I group was as much as 75% (6 patients died), in patients of the II group - 45,8% (13 patients died).

Conclusions: Complex therapy, which is based on Ukrain administration in neo-adjuvant regimen allowed to improve both direct and postponed results of treatment of RC-patients.